WASHINGTON (Reuters) - An “inspection blitz” prompted by two high-profile body parts scandals have turned up no serious problems at most firms that deal with human tissue, the Food and Drug Administration said on Tuesday.Tissue collection companies process a variety of human material from deceased donors, such as bone, ligaments, skin and tendons, that can be transplanted into patients.
